According to the Jimin Health announcement, due to its own capital requirements, Shuangge Group, the controlling shareholder of the company and shareholder holding 5% or more of the shares, plans to reduce the total holdings of the company by no more than 10,501,812 shares through centralized bidding and bulk transactions, that is, no more than 2% of the company's total share capital. Among them, centralized bidding and bulk transactions will each reduce their holdings by no more than 1% of the total share capital. The holdings reduction period is from September 14, 2026 to December 13, 2026. As of the disclosure date of the announcement, Shuangge Group held 122,748,520 shares of the company, accounting for 23.38% of the company's total share capital. This reduction in holdings will not result in a change in the company's control, and there is uncertainty about the implementation of the holdings reduction.

According to the Jimin Health announcement, due to its own capital requirements, Shuangge Group, the controlling shareholder of the company and shareholder holding 5% or more of the shares, plans to reduce the total holdings of the company by no more than 10,501,812 shares through centralized bidding and bulk transactions, that is, no more than 2% of the company's total share capital. Among them, centralized bidding and bulk transactions will each reduce their holdings by no more than 1% of the total share capital. The holdings reduction period is from September 14, 2026 to December 13, 2026. As of the disclosure date of the announcement, Shuangge Group held 122,748,520 shares of the company, accounting for 23.38% of the company's total share capital. This reduction in holdings will not result in a change in the company's control, and there is uncertainty about the implementation of the holdings reduction.